Drug combination may become new standard treatment for advanced kidney cancer
VIDEO: Toni K. Choueiri, MD details encouraging findings on the combination of the immunotherapy drug avelumab plus axitinib, a targeted agent, in treating advanced kidney cancer. view more BOSTON – A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer,…